ssmuБюллетень сибирской медициныBulletin of Siberian Medicine1682-03631819-3684Siberian State Medical University, the Ministry of Healthcare of the Russian Federation10.20538/1682-0363-2020-3-188-197ssmu-3003Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEW AND LECTURESАдипонектин и инсулин: молекулярные механизмы реализации метаболических нарушенийAdiponectin and insulin: molecular mechanisms of metabolic disordershttps://orcid.org/0000-0003-4321-8977УчасоваЕ. Г.UchasovaE. G.

канд. мед. наук, ст. науч. сотрудник, лаборатория исследований гомеостаза, диагностикасердечно-сосудистых заболеваний

Россия, 650002, г. Кемерово, Сосновый бул., 6

 

evg.uchasova@yandex.ruhttps://orcid.org/0000-0002-7780-829XГруздеваО. В.GruzdevaO. V.

д-р мед. наук, зав. лабораторией исследований гомеостаза, отдел диагностики сердечно-сосудистых заболеваний

Россия, 650002, г. Кемерово, Сосновый бул., 6

https://orcid.org/0000-0003-3996-3325БеликЕ. В.BelikE. V.

мл. науч. сотрудник, лаборатория исследований гомеостаза отдел, диагностики сердечно-сосудистых заболеваний

Россия, 650002, г. Кемерово, Сосновый бул., 6

https://orcid.org/0000-0002-6890-3287ДылеваЮ. А.DylevaYu. A.

канд. мед. наук, ст. науч. сотрудник, лаборатория исследований гомеостаза отдел, диагностики сердечно-сосудистых заболеваний

Россия, 650002, г. Кемерово, Сосновый бул., 6

Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний (НИИ КПССЗ)РоссияFederal State Budgetary Scientific Institution Research Institute for Complex Issues of Cardiovascular DiseasesRussian Federation202007102020193188197Copyright © Учасова Е.Г., Груздева О.В., Белик Е.В., Дылева Ю.А., 20202020Учасова Е.Г., Груздева О.В., Белик Е.В., Дылева Ю.А.Uchasova E.G., Gruzdeva O.V., Belik E.V., Dyleva Y.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://bulletin.ssmu.ru/jour/article/view/3003адипонектининсулинадипоцитыожирениеadiponectininsulinadipocytesobesityReferencesMaeda K. СDNA Cloning and expression of a novel adipose specific collagen-like factor, apM1 (dioseost Abundant Gene Transcript 1). Biochem. Biophys. Res. Commun. 2012; 425 (3): 556–559. DOI: 10.1016/j.bbrc. 2012.08.023.Maeda K. СDNA Cloning and expression of a novel adipose specific collagen-like factor, apM1 (dioseost Abundant Gene Transcript 1). Biochem. Biophys. Res. Commun. 2012; 425 (3): 556–559. DOI: 10.1016/j.bbrc. 2012.08.023.Liu Y., Sweeney G., Adiponectin action in skeletal muscle. Best Pract. Res. Clin. Endocrinol. Metab. 2014; 28 (1): 33–41. DOI: 10.1016/j.beem.2013.08. 0034.Liu Y., Sweeney G., Adiponectin action in skeletal muscle. Best Pract. Res. Clin. Endocrinol. Metab. 2014; 28 (1): 33–41. DOI: 10.1016/j.beem.2013.08. 0034.Crawford L.J.A., Peake R., Price S., Morris T.C.M., Irvine A.E. Adiponectin is produced by lymphocytes and is a negative regulator of granulopoiesis. J. Leukoc. Biol. 2010; 88 (4): 807–811. DOI: 10.1189/jlb.1109723.Crawford L.J.A., Peake R., Price S., Morris T.C.M., Irvine A.E. Adiponectin is produced by lymphocytes and is a negative regulator of granulopoiesis. J. Leukoc. Biol. 2010; 88 (4): 807–811. DOI: 10.1189/jlb.1109723.Akingbemi B.T. Adiponectin receptors in energy homeostasis and obesity pathogenesis. Prog. Mol. Biol. Transl. Sci. 2013:114; 317–342. DOI: 10. 1016/B978-0-12-386933-3.00009-1.Akingbemi B.T. Adiponectin receptors in energy homeostasis and obesity pathogenesis. Prog. Mol. Biol. Transl. Sci. 2013:114; 317–342. DOI: 10. 1016/B978-0-12-386933-3.00009-1.Беспалова И.Д., Рязанцева Н.В., Калюжин В.В., Осихов И.А., Мурашев Б.Ю., Медянцев Ю.А., Рудницкий В.А. Гендерные особенности взаимосвязи гормональной активности жировой ткани и провоспалительного статуса при гипертонической болезни с метаболическим синдромом. Бюллетень сибирской медицины. 2014; 13 (5): 12–19. DOI: 10.20538/1682-0363-2014-5-12-19.Bespalova I.D., Ryazantseva N.V., Kalyuzhin V.V., Osikhov I.A., Murashev B.Y., Medyantsev Y.A., Rudnitsky V.A. Gender features of the relation of hormonal activity adipose tissue and pro-inflammatory status in hypertension with metabolic syndrome. Bulletin of Siberian Medicine. 2014; 13 (5): 12–19. DOI: 10.20538/1682-0363-2014-5-12-19 (in Russ.)Wang Y., Lu G., Wong W.P.S., Vliegenthart J.F.G., Gerwig G.J., Lam K.S.L., Cooper G.J., Xu A. Proteomic and functional characterization of endogenous adiponectin purified from fetal bovine serum. Proteomics. 2004; 4 (12): 3933–3942. DOI: 10. 1002/pmic.200400826.Wang Y., Lu G., Wong W.P.S., Vliegenthart J.F.G., Gerwig G.J., Lam K.S.L., Cooper G.J., Xu A. Proteomic and functional characterization of endogenous adiponectin purified from fetal bovine serum. Proteomics. 2004; 4 (12): 3933–3942. DOI: 10. 1002/pmic.200400826.Wang Y., Lam K.S., Yau M.H., Xu. A. Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem. J. 2008; 409 (3): 623–633. DOI: 10.1042/BJ20071492.Wang Y., Lam K.S., Yau M.H., Xu. A. Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem. J. 2008; 409 (3): 623–633. DOI: 10.1042/BJ20071492.Waki H., Yamauchi T., Kamon J., Kita S., Ito Y., Hada Y., Uchida S., Tsuchida A., Takekawa S., Kadowaki T. Generation of globular fragment of adiponectin by leukocyte elastase secreted by monocytic cell line THP-1. Endocrinology. 2005; 146 (2): 790–796. DOI: 10.1210/en. 2004-1096.Waki H., Yamauchi T., Kamon J., Kita S., Ito Y., Hada Y., Uchida S., Tsuchida A., Takekawa S., Kadowaki T. Generation of globular fragment of adiponectin by leukocyte elastase secreted by monocytic cell line THP-1. Endocrinology. 2005; 146 (2): 790–796. DOI: 10.1210/en. 2004-1096.Halberg N., Schraw T.D., Wang Z.V., Kim J.Y., Yi J., Hamilton M.P., Luby-Phelps K., Scherer P.E. Systemic fate of the adipocyte-derived factor adiponectin. Diabetes. 2009; 58 (9): 1961–1970. DOI: 10.2337/db08-1750.Halberg N., Schraw T.D., Wang Z.V., Kim J.Y., Yi J., Hamilton M.P., Luby-Phelps K., Scherer P.E. Systemic fate of the adipocyte-derived factor adiponectin. Diabetes. 2009; 58 (9): 1961–1970. DOI: 10.2337/db08-1750.Pajvani U.B., Hawkins M., Combs T.P., Rajala M.W., Doebber T., Berger J.P., Wagner J.A., Wu M., Knopps A., Xiang A.H., Utzschneider K.M., Kahn S.E., Olefsky J.M., Buchanan T.A., Scherer P.E. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J. Biol. Chem. 2004; 279 (13): 12152–12162. DOI: 10.1074/jbc.M311113200.Pajvani U.B., Hawkins M., Combs T.P., Rajala M.W., Doebber T., Berger J.P., Wagner J.A., Wu M., Knopps A., Xiang A.H., Utzschneider K.M., Kahn S.E., Olefsky J.M., Buchanan T.A., Scherer P.E. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J. Biol. Chem. 2004; 279 (13): 12152–12162. DOI: 10.1074/jbc.M311113200.Wang Y., A. Xu, C. Knight, L.Y. Xu, Cooper G.J.S. Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity. J. Biol. Chem. 2002; 277 (22): 19521–19529. DOI: 10.1074/jbc.M200601200.Wang Y., A. Xu, C. Knight, L.Y. Xu, Cooper G.J.S. Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity. J. Biol. Chem. 2002; 277 (22): 19521–19529. DOI: 10.1074/jbc.M200601200.Fruebis J., Tsao T.S., Javorschi S., Ebbets-Reed D., Erickson M.R.S., Yen F.T., Bihain B.E., Lodish H.F. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. USA. 2001; 98 (4): 2005–2010. DOI: 10.1073/pnas.98.4.2005.Fruebis J., Tsao T.S., Javorschi S., Ebbets-Reed D., Erickson M.R.S., Yen F.T., Bihain B.E., Lodish H.F. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. USA. 2001; 98 (4): 2005–2010. DOI: 10.1073/pnas.98.4.2005.Tsao T.S.S., Murrey H.E., Hug C., Lee D.H., Lodish H.F. Oligomerization statedependent activation of NF-κB signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J. Biol. Chem. 2002; 277 (33): 29359–29362. DOI: 10.1074/jbc.C200312200.Tsao T.S.S., Murrey H.E., Hug C., Lee D.H., Lodish H.F. Oligomerization statedependent activation of NF-κB signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J. Biol. Chem. 2002; 277 (33): 29359–29362. DOI: 10.1074/jbc.C200312200.Tsao T.S., Tomas E., Murrey H.E., Hug C., Lee D.H., Ruderman N.B., Heuser J.E., Lodish H.F. Role of disulfide bonds in Acrp30/Adiponectin structure and signaling specificity: different oligomers activate different signal transduction pathways. J. Biol. Chem. 2003; 278 (50): 50810–50817. DOI: 10.1074/jbc.M309469200.Tsao T.S., Tomas E., Murrey H.E., Hug C., Lee D.H., Ruderman N.B., Heuser J.E., Lodish H.F. Role of disulfide bonds in Acrp30/Adiponectin structure and signaling specificity: different oligomers activate different signal transduction pathways. J. Biol. Chem. 2003; 278 (50): 50810–50817. DOI: 10.1074/jbc.M309469200.Hada Y., Yamauchi T., Waki H., Tsuchida A., Hara K., Yago H., Miyazaki O., Ebinuma H., Kadowaki T. Selective purification and characterization of adiponectin multimer species from human plasma. Biochem. Biophys. Res. Commun. 2007; 356 (2): 487–493. DOI: 10.1016/j.bbrc.2007.03.004.Hada Y., Yamauchi T., Waki H., Tsuchida A., Hara K., Yago H., Miyazaki O., Ebinuma H., Kadowaki T. Selective purification and characterization of adiponectin multimer species from human plasma. Biochem. Biophys. Res. Commun. 2007; 356 (2): 487–493. DOI: 10.1016/j.bbrc.2007.03.004.Peake P.W., Kriketos A.D., Campbell L.V., Shen Y., Charlesworth J.A. The metabolism of isoforms of human adiponectin: studies in human subjects and in experimental animals. Eur. J. Endocrinol. 2005; 153 (3): 409–417. DOI: 10.1530/eje.1.01978.Peake P.W., Kriketos A.D., Campbell L.V., Shen Y., Charlesworth J.A. The metabolism of isoforms of human adiponectin: studies in human subjects and in experimental animals. Eur. J. Endocrinol. 2005; 153 (3): 409–417. DOI: 10.1530/eje.1.01978.Pischon T., Hotamisligil G.S., Rimm E.B. Adiponectin: stability in plasma over 36 hours and within-person variation over 1 year. Clin. Chem. 2003; 49 (4): 650–652. DOI: 10.1373/49.4.650.Pischon T., Hotamisligil G.S., Rimm E.B. Adiponectin: stability in plasma over 36 hours and within-person variation over 1 year. Clin. Chem. 2003; 49 (4): 650–652. DOI: 10.1373/49.4.650.Tanabe H., Fujii Y., Okada-Iwabu M., Iwabu M., Nakamura Y., Hosaka T. Crystal structures of the human adiponectin receptors. Nature. 2015; 520 (7547): 312–316. DOI: 10.1038/nature14301.Tanabe H., Fujii Y., Okada-Iwabu M., Iwabu M., Nakamura Y., Hosaka T. Crystal structures of the human adiponectin receptors. Nature. 2015; 520 (7547): 312–316. DOI: 10.1038/nature14301.Ruan H., Dong L.Q. Adiponectin signaling and function in insulin target tissues. J. Mol. Cell Biol. 2016; 8: 101–109. DOI: 10.1093/jmcb/mjw014.Ruan H., Dong L.Q. Adiponectin signaling and function in insulin target tissues. J. Mol. Cell Biol. 2016; 8: 101–109. DOI: 10.1093/jmcb/mjw014.Mao X., Kikani C.K., Riojas R.A., Langlais P., Wang L., Ramos F.J., Fang Q., Christ-Roberts C.Y., Hong J.Y., Kim R.Y., Liu F., Dong L.Q. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat. Cell Biol. 2006; 8 (5): 516–523. DOI: 10.1038/ncb1404.Mao X., Kikani C.K., Riojas R.A., Langlais P., Wang L., Ramos F.J., Fang Q., Christ-Roberts C.Y., Hong J.Y., Kim R.Y., Liu F., Dong L.Q. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat. Cell Biol. 2006; 8 (5): 516–523. DOI: 10.1038/ncb1404.Buechler C., Wanninger J., Neumeier M. Adiponectin receptor binding proteins – recent advances in elucidating adiponectin signalling pathways. FEBS Lett. 2010; 584 (20): 4280–4286. DOI: 10.1016/j.febslet.2010.09.035.Buechler C., Wanninger J., Neumeier M. Adiponectin receptor binding proteins – recent advances in elucidating adiponectin signalling pathways. FEBS Lett. 2010; 584 (20): 4280–4286. DOI: 10.1016/j.febslet.2010.09.035.Deepa S.S., Zhou L., Ryu J., Wang C., Mao X., Li C., Zhang N., Musi N., DeFronzo R.A., Liu F., Dong L.Q. APPL1 mediates adiponectin-induced LKB1 cytosolic localization through the PP2A-PKCzeta signaling pathway. Mol. Endocrinol. 2011; 25 (10): 1773–1785. DOI: 10.1210/me. 2011-0082.Deepa S.S., Zhou L., Ryu J., Wang C., Mao X., Li C., Zhang N., Musi N., DeFronzo R.A., Liu F., Dong L.Q. APPL1 mediates adiponectin-induced LKB1 cytosolic localization through the PP2A-PKCzeta signaling pathway. Mol. Endocrinol. 2011; 25 (10): 1773–1785. DOI: 10.1210/me. 2011-0082.Gormand A., Henriksson E., Ström K., Jensen T.E., Sakamoto K., Göransson O., Regulation of AMP-activated protein kinase by LKB1 and CaMKK in adipocytes. J. Cell. Biochem. 2011; 112: 1364–1375. DOI: 10.1002/jcb.23053.Gormand A., Henriksson E., Ström K., Jensen T.E., Sakamoto K., Göransson O., Regulation of AMP-activated protein kinase by LKB1 and CaMKK in adipocytes. J. Cell. Biochem. 2011; 112: 1364–1375. DOI: 10.1002/jcb.23053.Woods A., Dickerson K., Heath R., Hong S.P., Momcilovic M., Johnstone S.R., Carlson M. Carling D. Ca2+/calmodulin-dependent protein kinase kinase-β acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab. 2005; 2 (1): 21–33. DOI: 10.1016/j.cmet.2005.06.005.Woods A., Dickerson K., Heath R., Hong S.P., Momcilovic M., Johnstone S.R., Carlson M. Carling D. Ca2+/calmodulin-dependent protein kinase kinase-β acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab. 2005; 2 (1): 21–33. DOI: 10.1016/j.cmet.2005.06.005.Zhou L., Deepa S.S., Etzler J.C., Ryu J., Mao X., Fang Q., Liu D.D., Torres J.M., Jia W., Lechleiter J.D., Liu F., Dong L.Q. Adiponectin activates AMP-activated protein kinase in muscle cells via APPL1/LKB1-dependent and phospholipase C/Ca2+/Ca2+/calmodulin-dependent protein kinase kinase dependent pathways. J. Biol. Chem. 2009; 284 (33): 22426–22435. DOI: 10.1074/jbc.M109.028357.Zhou L., Deepa S.S., Etzler J.C., Ryu J., Mao X., Fang Q., Liu D.D., Torres J.M., Jia W., Lechleiter J.D., Liu F., Dong L.Q. Adiponectin activates AMP-activated protein kinase in muscle cells via APPL1/LKB1-dependent and phospholipase C/Ca2+/Ca2+/calmodulin-dependent protein kinase kinase dependent pathways. J. Biol. Chem. 2009; 284 (33): 22426–22435. DOI: 10.1074/jbc.M109.028357.Iwabu M., Yamauchi T., Okada-Iwabu M., Sato K., Nakagawa T., Funata M. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature. 2010; 464 (7393): 1313–1319. DOI: 10.1038/ nature08991.Iwabu M., Yamauchi T., Okada-Iwabu M., Sato K., Nakagawa T., Funata M. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature. 2010; 464 (7393): 1313–1319. DOI: 10.1038/ nature08991.Kahn B.B., Alquier T., Carling D., Hardie D.G. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005; 1 (1): 15–25. DOI: 10.1016/j.cmet.2004.12.003Kahn B.B., Alquier T., Carling D., Hardie D.G. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005; 1 (1): 15–25. DOI: 10.1016/j.cmet.2004.12.003Ceddia R.B., Somwar R., Maida A., Fang X., Bikopoulos G., Sweeney G. Globular adiponectin increases GLUT4 translocation and glucose uptake but reduces glycogen synthesis in rat skeletal muscle cells. Diabetologia. 2005; 48 (1): 132–139. DOI: 10.1007/s00125-004-1609-y.Ceddia R.B., Somwar R., Maida A., Fang X., Bikopoulos G., Sweeney G. Globular adiponectin increases GLUT4 translocation and glucose uptake but reduces glycogen synthesis in rat skeletal muscle cells. Diabetologia. 2005; 48 (1): 132–139. DOI: 10.1007/s00125-004-1609-y.Jørgensen S.B., Nielsen J.N., Birk J.B., Olsen G.S., Viollet B., Andreelli F., Schjerling P., Vaulont S., Hardie D.G., Hansen B.F., Richter E.A., Wojtaszewski J.F. The alpha2-5’AMP-activated protein kinase is a site 2 glycogen synthase kinase in skeletal muscle and is responsive to glucose loading. Diabetes. 2004; 53 (12): 3074–3081. DOI: 10.2337/diabetes.53.12.3074.Jørgensen S.B., Nielsen J.N., Birk J.B., Olsen G.S., Viollet B., Andreelli F., Schjerling P., Vaulont S., Hardie D.G., Hansen B.F., Richter E.A., Wojtaszewski J.F. The alpha2-5’AMP-activated protein kinase is a site 2 glycogen synthase kinase in skeletal muscle and is responsive to glucose loading. Diabetes. 2004; 53 (12): 3074–3081. DOI: 10.2337/diabetes.53.12.3074.Jäger S.S., Handschin C.C., St-Pierre J.J., Spiegelman B.M. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc. Natl. Acad. Sci. USA. 2007; 104 (29): 12017–12022. DOI: 10.1073/pnas. 0705070104.Jäger S.S., Handschin C.C., St-Pierre J.J., Spiegelman B.M. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc. Natl. Acad. Sci. USA. 2007; 104 (29): 12017–12022. DOI: 10.1073/pnas. 0705070104.Rodgers J.T., Lerin C., Haas W., Gygi S.P., Spiegelman B.M., Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1a and SIRT1. Nature. 2005; 434 (7029): 113–118, DOI: 10.1038/nature03314.1.Rodgers J.T., Lerin C., Haas W., Gygi S.P., Spiegelman B.M., Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1a and SIRT1. Nature. 2005; 434 (7029): 113–118, DOI: 10.1038/nature03314.1.Thorn S.L., Gollob M.H., Harper M.E., Beanlands R.S., Dekemp R.A., Dasilva J.N. Chronic AMPK activity dysregulation produces myocardial insulin resistance in the human Arg302Gln-PRKAG2 glycogen storage disease mouse model. EJNMMI Res. 2013; 3 (1): 48. DOI: 10.1186/2191-219X-3-48.Thorn S.L., Gollob M.H., Harper M.E., Beanlands R.S., Dekemp R.A., Dasilva J.N. Chronic AMPK activity dysregulation produces myocardial insulin resistance in the human Arg302Gln-PRKAG2 glycogen storage disease mouse model. EJNMMI Res. 2013; 3 (1): 48. DOI: 10.1186/2191-219X-3-48.Stöckli J., Davey J.R, Hohnen-Behrens C., Xu A., James D.E., Ramm G. Regulation of glucose transporter 4 translocation by the Rab guanosine triphosphatase-activating protein AS160/TBC1D4: role of phosphorylation and membrane association. Mol. Endocrinol. 2008; 22 (12): 2703–2715. DOI: 10. 1210/me.2008-0111.Stöckli J., Davey J.R, Hohnen-Behrens C., Xu A., James D.E., Ramm G. Regulation of glucose transporter 4 translocation by the Rab guanosine triphosphatase-activating protein AS160/TBC1D4: role of phosphorylation and membrane association. Mol. Endocrinol. 2008; 22 (12): 2703–2715. DOI: 10. 1210/me.2008-0111.Wang C., Mao X., Wang L., Liu M., Wetzel M.D., Guan K.L. Dong L.Q., Liu F. Adiponectin sensitizes insulin signaling by reducing p70 S6 kinase-mediated serine phosphorylation of IRS-1. J. Biol. Chem. 2007; 282 (11): 7991–7996. DOI: 10.1074/jbc.M700098200.Wang C., Mao X., Wang L., Liu M., Wetzel M.D., Guan K.L. Dong L.Q., Liu F. Adiponectin sensitizes insulin signaling by reducing p70 S6 kinase-mediated serine phosphorylation of IRS-1. J. Biol. Chem. 2007; 282 (11): 7991–7996. DOI: 10.1074/jbc.M700098200.Combs T.P., Marliss E.B. Adiponectin signaling in the liver. Rev. Endocr. Metab. Disord. 2014; 15 (2): 137–147. DOI: 10.1007/s11154-013-9280-6.Combs T.P., Marliss E.B. Adiponectin signaling in the liver. Rev. Endocr. Metab. Disord. 2014; 15 (2): 137–147. DOI: 10.1007/s11154-013-9280-6.Kim J., Kundu M., Viollet B., Guan K.L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 2011; 13 (2): 132–141. DOI: 10.1038/ncb2152.Kim J., Kundu M., Viollet B., Guan K.L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 2011; 13 (2): 132–141. DOI: 10.1038/ncb2152.Gamberi T., Modesti A., Magherini F., Souza D.M.D., Hawke T., Fiaschi T. Activation of autophagy by globular adiponectin is required for muscle differentiation. Biochim. Biophys. Acta. 2016; 1863 (4): 694–702. DOI:10.1016/j.bbamcr.2016.01.016.Gamberi T., Modesti A., Magherini F., Souza D.M.D., Hawke T., Fiaschi T. Activation of autophagy by globular adiponectin is required for muscle differentiation. Biochim. Biophys. Acta. 2016; 1863 (4): 694–702. DOI:10.1016/j.bbamcr.2016.01.016.Nollet M., Santucci-Darmanin S., Breuil V., Al-Sahlanee R., Cros C., Topi M., Momier D., Samson M., Pagnotta S., Cailleteau L., Battaglia S., Farlay D., Dacquin R., Barois N., Jurdic P., Boivin G., Heymann D., Lafont F., Lu S.S., Dempster D.W., Carle G.F., Pierrefite-Carle V. Autophagy in osteoblasts is involved in mineralization and bone homeostasis. Autophagy. 2014; 10 (11): 1965–1977. DOI:10.4161/auto.36182.Nollet M., Santucci-Darmanin S., Breuil V., Al-Sahlanee R., Cros C., Topi M., Momier D., Samson M., Pagnotta S., Cailleteau L., Battaglia S., Farlay D., Dacquin R., Barois N., Jurdic P., Boivin G., Heymann D., Lafont F., Lu S.S., Dempster D.W., Carle G.F., Pierrefite-Carle V. Autophagy in osteoblasts is involved in mineralization and bone homeostasis. Autophagy. 2014; 10 (11): 1965–1977. DOI:10.4161/auto.36182.Xie M., Zhang D., Dyck J.R.B., Li Y., Zhang H., Morishima M., Mann D.L., Taffet GE., Baldini A., Khoury D.S., Schneider M.D. A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc. Natl. Acad. Sci USA. 2006; 103 (46): 17378–17383. DOI: 10.1073/pnas.0604708103.Xie M., Zhang D., Dyck J.R.B., Li Y., Zhang H., Morishima M., Mann D.L., Taffet GE., Baldini A., Khoury D.S., Schneider M.D. A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc. Natl. Acad. Sci USA. 2006; 103 (46): 17378–17383. DOI: 10.1073/pnas.0604708103.Yan J., Gan L., Qi R., Sun C. Adiponectin decreases lipids deposition by p38 MAPK/ATF2 signaling pathway in muscle of broilers. Mol. Biol. Rep. 2013; 40 (12) 7017–7025. DOI: 10.1007/s11033-013-2821-y.Yan J., Gan L., Qi R., Sun C. Adiponectin decreases lipids deposition by p38 MAPK/ATF2 signaling pathway in muscle of broilers. Mol. Biol. Rep. 2013; 40 (12) 7017–7025. DOI: 10.1007/s11033-013-2821-y.Yamauchi T., Nio Y., Maki T., Kobayashi M., Takazawa T., Iwabu M. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat. Med. 2007; 13 (3): 332–339. DOI: 10.1038/nm1557.Yamauchi T., Nio Y., Maki T., Kobayashi M., Takazawa T., Iwabu M. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat. Med. 2007; 13 (3): 332–339. DOI: 10.1038/nm1557.Berg A.H., Combs T.P., Du X., Brownlee M., Scherer P.E. The adipocyte-secreted protein crp30 enhances hepatic insulin action. Nat. Med. 2001; 7 (8): 947–953. DOI: 10.1038/90992.Berg A.H., Combs T.P., Du X., Brownlee M., Scherer P.E. The adipocyte-secreted protein crp30 enhances hepatic insulin action. Nat. Med. 2001; 7 (8): 947–953. DOI: 10.1038/90992.Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 2001; 7 (8): 941–946. DOI: 10.1038/90984.Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 2001; 7 (8): 941–946. DOI: 10.1038/90984.Yoon M.J., Lee G.Y., Chung J.J., Ahn Y.H., 44. Hong S.H., Kim J.B. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator- activated receptor α. Diabetes. 2006; 55 (9): 2562–2570. DOI: 10.2337/db05-1322.Yoon M.J., Lee G.Y., Chung J.J., Ahn Y.H., 44. Hong S.H., Kim J.B. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator- activated receptor α. Diabetes. 2006; 55 (9): 2562–2570. DOI: 10.2337/db05-1322.Fu Y., Luo N., Klein R.L., Garvey W.T. Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J. Lipid. Res. 2005; 46 (7): 1369–1379. DOI: 10.1194/jlr.M400373-JLR200.Fu Y., Luo N., Klein R.L., Garvey W.T. Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J. Lipid. Res. 2005; 46 (7): 1369–1379. DOI: 10.1194/jlr.M400373-JLR200.Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 2001; 86 (5): 1930–1935. DOI: 10.1210/jcem.86.5.7463.Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 2001; 86 (5): 1930–1935. DOI: 10.1210/jcem.86.5.7463.Chang E, Choi J.M., Park S.E., Rhee E.J., Lee W.Y., Oh K.W., Park S.W., Park C.Y. Adiponectin deletion impairs insulin signaling in insulin-sensitive but not insulin-resistant 3T3-L1 adipocytes. Life Sci. 2015; 132: 93–100. DOI: 10.1016/j.lfs.2015.02.013.Chang E, Choi J.M., Park S.E., Rhee E.J., Lee W.Y., Oh K.W., Park S.W., Park C.Y. Adiponectin deletion impairs insulin signaling in insulin-sensitive but not insulin-resistant 3T3-L1 adipocytes. Life Sci. 2015; 132: 93–100. DOI: 10.1016/j.lfs.2015.02.013.Kern P.A., Di Gregorio G.B., Lu T., Rassouli N., Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes. 2003; 52 (7): 1779–1785. DOI: 10.2337/diabetes.52.7.1779.Kern P.A., Di Gregorio G.B., Lu T., Rassouli N., Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes. 2003; 52 (7): 1779–1785. DOI: 10.2337/diabetes.52.7.1779.Danielsson A., Ost A., Lystedt E., Kjolhede P., Gustavsson J., Nystrom F.H., Strålfors P. Insulin resistance in human adipocytes occurs downstream of IRS1 after surgical cell isolation but at the level of phosphorylation of IRS1 in type 2 diabetes. FEBS J. 2005; 272 (1): 141–151. DOI: 10.1111/j.1432-1033.2004.04396.x.Danielsson A., Ost A., Lystedt E., Kjolhede P., Gustavsson J., Nystrom F.H., Strålfors P. Insulin resistance in human adipocytes occurs downstream of IRS1 after surgical cell isolation but at the level of phosphorylation of IRS1 in type 2 diabetes. FEBS J. 2005; 272 (1): 141–151. DOI: 10.1111/j.1432-1033.2004.04396.x.Pessin J.E., Saltiel A.R. Signaling pathways in insulin action: molecular targets of insulin resistance. J. Clin. Invest. 2000; 106 (2): 165–169. DOI: 10.1172/JCI10582.Pessin J.E., Saltiel A.R. Signaling pathways in insulin action: molecular targets of insulin resistance. J. Clin. Invest. 2000; 106 (2): 165–169. DOI: 10.1172/JCI10582.Hammarstedt A., Graham T.E., Kahn B.B. Adipose tissue dysregulation and reduced insulin sensitivity in non-obese individuals with enlarged abdominal adipose cells. Diabetol. Metab. Syndr. 2012; 4 (1): 42. DOI: 10.1186/1758-5996-4-42.Hammarstedt A., Graham T.E., Kahn B.B. Adipose tissue dysregulation and reduced insulin sensitivity in non-obese individuals with enlarged abdominal adipose cells. Diabetol. Metab. Syndr. 2012; 4 (1): 42. DOI: 10.1186/1758-5996-4-42.Arbarash O., Gruzdeva O., Uchasova E., Belik E., Dyleva Y., Karetnikova V. Biochemical markers of type 2 diabetes as a late complication of myocardial infarction: a case-control study. Archives of Medical Science. 2017; 13 (2): 311–320. DOI: 10.5114/aoms.2017.65240.Arbarash O., Gruzdeva O., Uchasova E., Belik E., Dyleva Y., Karetnikova V. Biochemical markers of type 2 diabetes as a late complication of myocardial infarction: a case-control study. Archives of Medical Science. 2017; 13 (2): 311–320. DOI: 10.5114/aoms.2017.65240.Xin X., Zhou L., Reyes C.M., Liu F., Dong L.Q. APPL1mediates adiponectin-stimulated p38 MAPK activation by scaffolding the TAK1-MKK3-p38 MAPK pathway. Am. J. Physiol. Endocrinol. Metab. 2011; 300 (1): 103–110. DOI: 10.1152/ajpendo.00427.2010.Xin X., Zhou L., Reyes C.M., Liu F., Dong L.Q. APPL1mediates adiponectin-stimulated p38 MAPK activation by scaffolding the TAK1-MKK3-p38 MAPK pathway. Am. J. Physiol. Endocrinol. Metab. 2011; 300 (1): 103–110. DOI: 10.1152/ajpendo.00427.2010.Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003; 423 (6941): 762–769. DOI: 10.1038/nature01705.Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003; 423 (6941): 762–769. DOI: 10.1038/nature01705.Ghadge A.A., Harke S.M., Khadke S.P., Diwan A.G., Pankaj M., Kulkarni O.P., Ranjekar P.K., Kuvalekar A.A. Circulatory adipocytokines and lipid profile variations in type-2 diabetic subjects: desirable side-effects of antidiabetic drugs. Diabetes Metab. Syndr. 2014; 8 (4): 230–232. DOI: 10.1016/j.dsx.2014.09.010.Ghadge A.A., Harke S.M., Khadke S.P., Diwan A.G., Pankaj M., Kulkarni O.P., Ranjekar P.K., Kuvalekar A.A. Circulatory adipocytokines and lipid profile variations in type-2 diabetic subjects: desirable side-effects of antidiabetic drugs. Diabetes Metab. Syndr. 2014; 8 (4): 230–232. DOI: 10.1016/j.dsx.2014.09.010.Wang Z.V., Scherer P.E. Adiponectin, cardiovascular function, and hypertension. Hypertension. 2008; 51 (1): 8–14. DOI: 10.1161/HYPERTENSIONAHA.107.099424.Wang Z.V., Scherer P.E. Adiponectin, cardiovascular function, and hypertension. Hypertension. 2008; 51 (1): 8–14. DOI: 10.1161/HYPERTENSIONAHA.107.099424.Gruzdeva O., Uchasova E., Dyleva Y., Karetnikova V., Barbarash O., Akbasheva O. Early effects of treatment low-dose atorvastatin on markers of insulin resistance and inflammation in patients with myocardial infarction. Frontiers in Pharmacology. 2016; 7: 324. DOI: 10.3389/fphar.2016.00324.Gruzdeva O., Uchasova E., Dyleva Y., Karetnikova V., Barbarash O., Akbasheva O. Early effects of treatment low-dose atorvastatin on markers of insulin resistance and inflammation in patients with myocardial infarction. Frontiers in Pharmacology. 2016; 7: 324. DOI: 10.3389/fphar.2016.00324.Rasouli N., Yao-Borengasser A., Miles L.M., Elbein S.C., Kern P.A. Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. Am. J. Physiol. Endocrinol. Metab. 2006; 290: 42–46. DOI: 10.1152/ajpendo.00240.2005.Rasouli N., Yao-Borengasser A., Miles L.M., Elbein S.C., Kern P.A. Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. Am. J. Physiol. Endocrinol. Metab. 2006; 290: 42–46. DOI: 10.1152/ajpendo.00240.2005.Lin W.S., Chang H.M., Tai T.Y., Chuang L.M. Effect of thiazolidinedione on gene expression in NIH3T3-L1 adipocytes (Abstract). Diabetes. 1999; 48 (1): 217.Lin W.S., Chang H.M., Tai T.Y., Chuang L.M. Effect of thiazolidinedione on gene expression in NIH3T3-L1 adipocytes (Abstract). Diabetes. 1999; 48 (1): 217.Ghadge A.A., Khaire A.A., Kuvalekar A.A. Adiponectin: potential therapeutic target for metabolic syndrome. Cytokine Growth Factor Rev. 2018; 39: 151–158. DOI: 10.1016/j.cytogfr.2018.01.004.Ghadge A.A., Khaire A.A., Kuvalekar A.A. Adiponectin: potential therapeutic target for metabolic syndrome. Cytokine Growth Factor Rev. 2018; 39: 151–158. DOI: 10.1016/j.cytogfr.2018.01.004.Srivastava R.A.K., Pinkosky S.L., Filippov S., Hanselman J.C., Cramer C.T., Newton R.S. AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases: thematic review series: new lipid and lipoprotein targets for the treatment of cardiometabolic diseases. J. Lipid. Res. 2012; 53 (12): 2490–2514. DOI: 10.1194/jlr.R025882.Srivastava R.A.K., Pinkosky S.L., Filippov S., Hanselman J.C., Cramer C.T., Newton R.S. AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases: thematic review series: new lipid and lipoprotein targets for the treatment of cardiometabolic diseases. J. Lipid. Res. 2012; 53 (12): 2490–2514. DOI: 10.1194/jlr.R025882.

The authors declare that there are no conflicts of interest present.